1. Scrip
  2. >>R&D

Bispecifics Could Be A Threat To CAR-Ts, But Efficacy May Trump Convenience

 
• By Mandy Jackson

T-cell-engaging bispecific antibodies emerged at ASH as viable competitors for autologous T-cell therapies, but while their off-the-shelf availability is intriguing, it may be too early to say if their safety and efficacy beats CAR-Ts.

3d illustration of T cells or cancer cells,3d rendering.
CAR-T competition? It may come from bispecifics that engage T-cells. • Source: Shutterstock

Bispecific antibodies that are designed to target cancer cells and engage T-cells gained momentum at the recent American Society of Hematology (ASH) conference, prompting the question of whether these candidates could steal market share from chimeric antigen receptor T-cell (CAR-T) cell therapies that have generated a lot of excitement over the past few years.

It is probably too early to tell if bispecifics will offer efficacy and safety that beats the response rates seen with CAR-T therapies to date, including the two approved CD19-targeting CAR-T products – Novartis AG’s Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) from Gilead Sciences Inc.’s subsidiary Kite Pharma Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump’s executive order more rhetoric than action; industry grapples with Trump pricing plan; Hengrui set for this year’s biggest IPO; Sanofi’s exec’s advice to biotechs; and biotech deal return on investment falls.